Medical devices and injection moulding: why prototypes should use the intended production material

In medical projects, geometry-only validation is not enough. Evidence that supports registration starts with parts moulded in final production material.

•ITM technical team•Reading time: 7 min

A frequent pattern in medical-device development is clear: geometry is validated on additive or machined prototypes, design is approved, production tooling is built in intended production material, and the first serial lot reveals performance gaps. The issue is usually not CAD quality, but material mismatch during validation.

Injection-moulded medical-device component and prototype mould used to validate the production material
For medical parts, testing the intended production material provides more representative dimensional and mechanical evidence for the documented requirements.

Why material matters more in medical devices

In medical programmes, material is not a convenience choice. It is part of the registered product definition. So prototype evidence generated in substitute materials cannot be transferred to final validation with confidence.

  • Biocompatibility evidence (ISO 10993) is only valid on the registered polymer system.
  • Sterilisation resistance (steam or EtO) depends on material and moulding history.
  • Dimensional and mechanical behaviour under repeated loads is process- and material-specific.
Close-up of injection-moulded medical component for dimensional and mechanical validation
Process history and final resin define the mechanical and dimensional response of the real part.

Which evidence remains limited without intended production material

Key validation blocks in medical projects require parts moulded in final resin:

  • Mechanical properties in final geometry, including fibre-orientation effects where relevant.
  • Dimensional stability after thermal/humidity exposure and sterilisation cycles.
  • Chemical compatibility and functional response under real-use and cleaning conditions.

The right phase to run final-material injection

Final-material validation should start in prototype phase, not at first serial lot. At that stage, teams can still tune geometry, functional tolerances and gate strategy without expensive production-tool rework.

Using industrialisable prototype moulds under representative processing conditions can provide process data and CTQ evidence whose transfer limits should be documented against the production setup.

Prototype-to-registered-material comparison before production mould release
Validating in intended production material during prototype phase prevents costly late corrections in production tooling.

Regulatory impact: if critical deviations are found during first serial lots, IQ/OQ/PQ evidence can be delayed or partially repeated, affecting registration timelines.

The key question before production mould release

Before committing to production tooling, teams should ask: have we validated this medical part in intended production material, under real injection conditions, with documented dimensional and functional criteria?

If the answer is no, technical and timeline risk has already been accepted.

Cross-checked official technical sources

These sources support the general principles. Applicable acceptance criteria must be defined for the material grade, design, process, sector and agreed requirements.

Related articles

Next step

Turn this validation into project advantage

If you need to validate assembly, process behaviour and tolerances before production tooling, we can define a prototype route focused on engineering decisions, not assumptions.

Request a quote